# Abemaciclib With or Without Atezolizumab for mCRPC

> **NCT04751929** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 19 (actual)

## Conditions studied

- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04751929
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-20
- **Primary completion:** 2024-06-17
- **Final completion:** 2026-04-30
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04751929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04751929, "Abemaciclib With or Without Atezolizumab for mCRPC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04751929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*